The reason for care
What is the plan meant to help with? What other care could address that concern? What would count as a useful result?
Question cards
A calmer way
to ask about care.
You have a price page open and a list of questions in your head. Put the questions in order before a visit.
Bring the goal you want help with, the medicines and supplements you use, and any past test results. Ask for a discussion of your concern before choosing a treatment.
Finding a place for the discussion
Start with a health visit.
Telehealth brings a health visit to you by phone, through an online exchange or on a screen. An in-person clinic is another setting for that discussion.
Look for care with a licensed clinician, the health professional who assesses your concern. Ask whether that setting can assess your concern and arrange any in-person care needed.
For a visit, the doctor needs a licence or other permission that applies in whichever state you are in then. This U.S. guidance was checked on September 26, 2026. U.S. guidance on state licences
The Federation of State Medical Boards says state boards publish a doctor’s licence status and public records of discipline. What a board record can show
Use the doctor’s full name to search the right state board. Read the record rather than relying on a badge on a price page.
Ask which pharmacy would make and send a medicine. Then use the pharmacy lookup to check the name you were given.
Take these into the discussion
Questions that need clear answers.
The evidence
What published study in people supports this plan? Does it test MOTS-c itself, or something with a similar name?
The Food and Drug Administration (FDA) assesses medicines. Its records, checked on September 30, 2026, included no published study of MOTS-c treatment in people. Read the FDA evidence review
The exact ingredient
What is the full ingredient name? Who makes it? What rule permits its use?
Different versions of the ingredient were sold as MOTS-c, the FDA review reported; that review was checked on September 30, 2026. Why the full name matters
The bill and follow-up
What is included in the fee? Which tests and return visits cost extra? Who answers questions after the visit? What are the renewal and cancellation terms?
The basis for reassurance
What is known about harms in people? What remains unknown? What follow-up care would be available if a problem arose?
Read what the FDA could assessClaims to pause over
Medical-board advice checked on September 26, 2026, calls for more than picking a treatment from a menu for proper care. The medical boards’ guidance
Ask for a real discussion and room for your own questions. If treatment is offered without that discussion, pause the decision.
A “research-only” label means the product is meant for studies, not treatment in people.
The FDA’s letters said this label did not make it lawful to sell unapproved drugs across state lines for treatment. The letters were checked on September 26, 2026. Read about the rules for pharmacy-made medicine
Do not read this as permission to use a product sold within your state. If a product says “research-only,” pause before paying for treatment. Ask the doctor what law allows that exact product to be used for your care.